Research To Practice | Oncology Videos

Implications of Recent Data Sets for the Current and Future Management of Lung Cancer | Faculty Presentation 3: Immunotherapeutic and Other Novel Strategies for Metastatic NSCLC and Small Cell Lung Cancer — Aaron Lisberg, MD CME information and select publications

Implications of Recent Data Sets for the Current and Future Management of Lung Cancer | Faculty Presentation 1: Incorporation of Targeted and Immunotherapeutic Strategies into the Management of Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) — Luis Paz-Ares, MD, PhD CME information and select publications

Implications of Recent Data Sets for the Current and Future Management of Lung Cancer | Faculty Presentation 2: Targeted Therapy for Metastatic NSCLC — Zofia Piotrowska, MD, MHS CME information and select publications

Featuring perspectives from Dr Samuel J Klempner, including the following topics: Introduction (0:00) Case: An 80-year-old woman with newly diagnosed metastatic microsatellite-stable (MSS), HER2-negative lower esophageal adenocarcinoma; PD-L1 CPS 60 — Warren S Brenner, MD (13:36) Case: A 61-year-old man with newly diagnosed HER2-negative gastroesophageal junction adenocarcinoma and worsening dysphagia with significant pain and nausea — Priya Rudolph, MD, PhD (19:05) Case: A 69-year-old man with chest pain and progressive dysphagia who is diagnosed with HER2-negative adenocarcinoma of the distal esophagus with locoregional lymph node involvement — Matthew R Strickland, MD (23:22) Case: A 55-year-old man and Iraq War veteran with MSS, HER2-positive recurrent esophageal cancer after first-line FOLFOX/trastuzumab/pembrolizumab and maintenance 5-FU/trastuzumab/pembrolizumab — Zanetta S Lamar, MD (29:52) Case: A 63-year-old man with newly diagnosed clinical Stage I lower esophageal cancer who undergoes esophagectomy; pathology reveals Stage IVA disease — Farshid Dayyani, MD, PhD (34:41) Investigator Survey (40:25) CME information and select publications

Featuring perspectives from Dr Aditya Bardia and Dr Sara M Tolaney, including the following topics: Introduction: Pan-tumor Approval of Novel Agents (0:00) Treatment of ER-Positive Localized Breast Cancer (7:49) Immunotherapy in Localized Breast Cancer (18:42) Antibody-Drug Conjugates in Metastatic Disease (Trastuzumab Deruxtecan, Sacituzumab Govitecan, Datopotamab Deruxtecan, Patritumab Deruxtecan) (37:21) CME information and select publications

Featuring perspectives from Dr Richard T Penson and Dr Krishnansu S Tewari, including the following topics: Introduction: Pan-tumor Indications for New Therapies (0:00) Endometrial Cancer (14:13) Treatment of Cervical Cancer (32:38) Updates in Ovarian Cancer (45:41) CME information and select publications

Featuring perspectives from Prof Van Cutsem, including the following topics: Introduction (0:00) Case: A woman in her early 50s who has undergone the neoadjuvant CROSS regimen and received surgery experiences local recurrence of PD-L1-negative gastroesophageal junction (GEJ) adenocarcinoma while receiving adjuvant nivolumab — Priya Rudolph, MD, PhD (15:56) Case: A man in his late 60s with localized Siewert Class III GEJ adenocarcinoma receives perioperative fluorouracil/leucovorin/oxaliplatin/docetaxel — Lai (Amber) Xu, MD, PhD (26:16) Case: A woman in her early 90s who has undergone radiation therapy for esophageal squamous cell carcinoma now experiences local recurrence; PD-L1 combined positive score (CPS) is 71 — G Richard Polkinghorn, MD (36:33) Case: A man in his late 60s with HER2-negative GEJ adenocarcinoma develops HER2-positive oligometastases — Matthew R Strickland, MD (42:17) Case: A woman in her early 70s with metastatic HER2-positive gastroesophageal cancer who received first-line FOLFOX/trastuzumab now experiences disease progression; PD-L1 CPS is 10 — Henna Malik, MD (47:53) Investigator Survey (52:26) CME information and select publications

Featuring perspectives from Dr Gail J Roboz, including the following topics: Introduction (0:00) Case: A man in his early 50s presents with fatigue and pancytopenia; bone marrow shows myelodysplastic syndromes (MDS) with 11% blasts; normal FISH MDS panel; next-generation sequencing shows BCOR, RUNX1 and UTAF1 mutations; normal metaphase cytogenetics — Warren S Brenner, MD (10:12) Case: An African American woman in her early 60s with high-risk MDS receives oral decitabine/cedazuridine — Henna Malik, MD (16:39) Case: A woman in her early 70s with anemia and low-grade MDS with ring sideroblasts experiences a poor response to erythropoietin and is now on luspatercept — Neil Morganstein, MD (22:15) Case: A woman in her early 60s with newly diagnosed acute myeloid leukemia (AML) and a FLT3-ITD mutation receives 7 + 3 induction with midostaurin induction, consolidation, allogeneic transplant and maintenance — Amany R Keruakous, MD, MS (35:23) Case: A man in his mid 60s with AML and an IDH1 mutation receives venetoclax/azacitidine/ivosidenib — Rebecca L Olin, MD, MSCE (53:23) Case: A woman in her late 30s with refractory leiomyosarcoma develops anthracycline-related secondary AML with an IDH2 mutation and is unable to obtain foundation funding assistance for enasidenib copays — Eric H Lee, MD, PhD (56:48) CME information and select publications

Featuring perspectives from Prof Mitesh J Borad, Dr Anthony El-Khoueiry, Dr Christopher R Flowers, Dr Sara A Hurvitz, Dr Thomas E Hutson, Dr Amrita Krishnan, Dr Ann S LaCasce, Dr Heather McArthur, Dr Bradley J Monk, Dr Kathleen N Moore, Dr Robert Z Orlowski and Dr Guru P Sonpavde, moderated by Dr Neil Love, co-moderated by Dr Stephen "Fred" Divers, including the following topics: Introduction (0:00) Triple-Negative Breast Cancer — Heather McArthur, MD, MPH (6:59) HER2-Positive Breast Cancer — Sara A Hurvitz, MD, FACP (44:04) CME information and select publications

Featuring perspectives from Prof Mitesh J Borad, Dr Anthony El-Khoueiry, Dr Christopher R Flowers, Dr Sara A Hurvitz, Dr Thomas E Hutson, Dr Amrita Krishnan, Dr Ann S LaCasce, Dr Heather McArthur, Dr Bradley J Monk, Dr Kathleen N Moore, Dr Robert Z Orlowski and Dr Guru P Sonpavde, moderated by Dr Neil Love, co-moderated by Dr Stephen "Fred" Divers, including the following topics: Introduction (0:00) Optimizing the Current Management of Multiple Myeloma — Robert Z Orlowski, MD, PhD (3:44) CAR (Chimeric Antigen Receptor) T-Cell Therapy, Bispecific Antibodies and Other Novel Approaches — Amrita Krishnan, MD (32:37) CME information and select publications

Featuring perspectives from Prof Mitesh J Borad, Dr Anthony El-Khoueiry, Dr Christopher R Flowers, Dr Sara A Hurvitz, Dr Thomas E Hutson, Dr Amrita Krishnan, Dr Ann S LaCasce, Dr Heather McArthur, Dr Bradley J Monk, Dr Kathleen N Moore, Dr Robert Z Orlowski and Dr Guru P Sonpavde, moderated by Dr Neil Love, co-moderated by Dr Stephen "Fred" Divers, including the following topics: Introduction (0:00) Ovarian Cancer — Kathleen N Moore, MD, MS (4:14) Endometrial and Cervical Cancers — Bradley J Monk, MD (41:09) CME information and select publications

Featuring perspectives from Prof Mitesh J Borad, Dr Anthony El-Khoueiry, Dr Christopher R Flowers, Dr Sara A Hurvitz, Dr Thomas E Hutson, Dr Amrita Krishnan, Dr Ann S LaCasce, Dr Heather McArthur, Dr Bradley J Monk, Dr Kathleen N Moore, Dr Robert Z Orlowski and Dr Guru P Sonpavde, moderated by Dr Neil Love, co-moderated by Dr Stephen "Fred" Divers, including the following topics: Introduction (0:00) Biliary Tract and Pancreatic Cancer — Mitesh J Borad, MD (3:42) Hepatocellular Carcinoma — Anthony El-Khoueiry, MD (33:25) CME information and select publications

Featuring perspectives from Prof Mitesh J Borad, Dr Anthony El-Khoueiry, Dr Christopher R Flowers, Dr Sara A Hurvitz, Dr Thomas E Hutson, Dr Amrita Krishnan, Dr Ann S LaCasce, Dr Heather McArthur, Dr Bradley J Monk, Dr Kathleen N Moore, Dr Robert Z Orlowski and Dr Guru P Sonpavde, moderated by Dr Neil Love, co-moderated by Dr Stephen "Fred" Divers, including the following topics: Introduction (0:00) Renal Cell Carcinoma — Thomas E Hutson, DO, PharmD (6:19) Urothelial Bladder Cancer — Guru P Sonpavde, MD (34:59) CME information and select publications

Featuring perspectives from Prof Mitesh J Borad, Dr Anthony El-Khoueiry, Dr Christopher R Flowers, Dr Sara A Hurvitz, Dr Thomas E Hutson, Dr Amrita Krishnan, Dr Ann S LaCasce, Dr Heather McArthur, Dr Bradley J Monk, Dr Kathleen N Moore, Dr Robert Z Orlowski and Dr Guru P Sonpavde, moderated by Dr Neil Love, co-moderated by Dr Stephen "Fred" Divers, including the following topics: Introduction (0:00) Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma — Ann S LaCasce, MD, MMSc (8:26) Follicular Lymphoma and Mantle Cell Lymphoma — Christopher R Flowers, MD, MS (42:55) CME information and select publications

Featuring perspectives from Dr David M O'Malley, including the following topics: Introduction: 2023 American Oncology Network Summit (0:00) Case: A woman in her late 70s with metastatic BRCA wild-type, homologous recombination deficiency-negative high-grade serous ovarian cancer (HGSOC) experiences disease progression after 6 lines of systemic therapy; PS = 0 — Dana M Chase, MD (8:31) Case: A woman in her mid 80s is diagnosed with a germline BRCA2 (gBRCA2) mutation and Stage IV HGSOC; CA-125 32,000 U/mL — Mamta Choksi, MD (21:27) Case: A woman in her mid 40s who has undergone TAH/BSO for Stage IC HGSOC with a gBRCA2 mutation receives adjuvant carboplatin/paclitaxel — Priya Rudolph, MD, PhD (32:47) Case: A woman in her early 60s with a gBRCA1 mutation and HGSOC who has undergone debulking surgery and carboplatin/paclitaxel develops anemia on maintenance olaparib — Karim ElSahwi, MD (40:56) Case: A woman in her mid 60s with recurrent BRCA wild-type HGSOC is enrolled in a trial of tumor treating fields and paclitaxel — Lyndsay J Willmott, MD (54:01) Case: A woman in her early 50s with multiregimen-recurrent FR-alpha-positive OC and a gBRCA1 mutation receives mirvetuximab soravtansine — Kellie E Schneider, MD (58:50) CME information and select publications

Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Harold Burstein, Dr Asher Chanan-Khan, Dr Komal Jhaveri, Dr Brad S Kahl, Dr Alicia K Morgans, Dr Philip A Philip, Dr Gregory J Riely, Dr Matthew R Smith and Dr Heather Wakelee, including the following topics: Introduction (0:00) Chronic Lymphocytic Leukemia (CLL): Considerations for Front-Line Treatment — Dr Kahl (1:48) Treatment of Relapsed/Refractory CLL; Novel and Investigational Strategies — Dr Chanan-Khan (35:38) Clinical Questions and Cases (49:58) CME information and select publications

Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Harold Burstein, Dr Asher Chanan-Khan, Dr Komal Jhaveri, Dr Brad S Kahl, Dr Alicia K Morgans, Dr Philip A Philip, Dr Gregory J Riely, Dr Matthew R Smith and Dr Heather Wakelee, including the following topics: Introduction (0:00) Gastroesophageal Cancers — Dr Philip (1:42) Colorectal Cancer — Dr Bekaii-Saab (32:56) CME information and select publications

Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Harold Burstein, Dr Asher Chanan-Khan, Dr Komal Jhaveri, Dr Brad S Kahl, Dr Alicia K Morgans, Dr Philip A Philip, Dr Gregory J Riely, Dr Matthew R Smith and Dr Heather Wakelee, including the following topics: Introduction (0:00) Non-Small Cell Lung Cancer Targeted Therapy — Dr Riely (4:09) Non-Small Cell Lung Cancer: Immunotherapeutic and Other Novel Strategies — Dr Wakelee (32:23) CME information and select publications

Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Harold Burstein, Dr Asher Chanan-Khan, Dr Komal Jhaveri, Dr Brad S Kahl, Dr Alicia K Morgans, Dr Philip A Philip, Dr Gregory J Riely, Dr Matthew R Smith and Dr Heather Wakelee, including the following topics: Introduction (0:00) Role of Hormonal Therapy in Prostate Cancer Management — Dr Smith (1:50) Clinical Questions and Cases (13:18) Evidence-Based Use of Other Therapeutic Approaches in Metastatic Castration-Resistant Prostate Cancer — Dr Morgans (26:08) Clinical Questions and Cases (38:01) CME information and select publications

Featuring perspectives from Dr Tanios Bekaii-Saab, Dr Harold Burstein, Dr Asher Chanan-Khan, Dr Komal Jhaveri, Dr Brad S Kahl, Dr Alicia K Morgans, Dr Philip A Philip, Dr Gregory J Riely, Dr Matthew R Smith and Dr Heather Wakelee, including the following topics: Introduction (0:00) ER-Positive Breast Cancer — Dr Burstein (3:57) Clinical Questions and Cases (16:47) Selection and Sequencing of Treatment for Relapsed ER-Positive Metastatic Breast Cancer — Dr Jhaveri (33:32) Clinical Questions and Cases (46:02) CME information and select publications

Featuring perspectives from Dr Matthew Lunning and Dr Laurie H Sehn, moderated by Dr Christopher R Flowers, including the following topics: Introduction (0:00) Up-Front Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Flowers (2:55) Selection and Sequencing of Therapy for Relapsed/Refractory (R/R) DLBCL — Dr Lunning (24:56) Role of CD20 x CD3 Bispecific Antibodies in the Management of DLBCL — Dr Sehn (44:06) CME information and select publications

Inside the Issue: Optimizing the Management of Nonmelanoma Skin Cancer | Faculty Presentation 1: Cutaneous Squamous Cell Carcinoma — Nikhil I Khushalani, MD CME information and select publications

Inside the Issue: Optimizing the Management of Nonmelanoma Skin Cancer | Faculty Presentation 2: Basal Cell Carcinoma — Anna C Pavlick, DO, MBA CME information and select publications

Featuring perspectives from Dr Nikhil I Khushalani and Dr Anna C Pavlick, including the following topics: Introduction: Why Did It Take So Long? (0:00) Cutaneous Squamous Cell Carcinoma — Dr Khushalani (13:47) Basal Cell Carcinoma — Dr Pavlick (39:57) CME information and select publications

Featuring perspectives from Dr Peter C Enzinger, including the following topics: Introduction (0:00) Case: A man in his mid 60s with HER2-positive metastatic squamous cell carcinoma of the esophagus develops progressive disease after treatment with 5-FU/cisplatin/trastuzumab; PD-L1 CPS 10 — Eric H Lee, MD, PhD (12:16) Case: A man in his early 50s with HER2-negative, microsatellite stable esophageal cancer and mediastinal lymphadenopathy receives concurrent chemoradiation (CROSS trial regimen) — Jennifer L Dallas, MD (37:23) Case: A frail woman in her early 80s with past medical history of cardiac issues is diagnosed with localized gastroesophageal junction adenocarcinoma — Priya Rudolph, MD, PhD (46:58) CME information and select publications

Featuring perspectives from Dr Naval Daver, including the following topics: Introduction: Biology, Classification, p53, Magrolimab (0:00) Case: A man in his early 70s with acute myeloid leukemia (AML) with a TP53 mutation, myelodysplastic syndromes (MDS)-related changes and complex cytogenetics who received CPX-351receives azacitidine/venetoclax and is now in palliative care — Anna Halpern, MD (9:06) Case: A woman in her late 50s with multiple comorbidities and FLT3-ITD-positive AML who experienced disease progression on azacitidine/venetoclax now receives gilteritinib — Bhavana (Tina) Bhatnagar, DO (17:01) Case: A woman in her early 70s with AML with FLT3-ITD and IDH1 mutations receives a hypomethylating agent with ivosidenib — Amany R Keruakous, MD, MS (29:10) Case: A man in his early 60s with newly diagnosed MDS with ring sideroblasts receives oral decitabine/cedazuridine — Khuda Dad Khan, MD, PhD (33:54) Case: A man in his mid 60s presents with copper deficiency and ring sideroblasts; genetic analysis reveals SF3B1 and DNMT3A mutations — Rachel J Cook, MD (42:25) Case: A woman in her early 70s with a history of extensively treated follicular lymphoma develops AML and receives CPX-351 — Ranju Gupta, MD (46:05) Case: A woman in her late 70s with newly diagnosed AML receives decitabine/venetoclax with concurrent voriconazole — Rebecca L Olin, MD, MSCE (51:05) Case: A woman in her late 90s is diagnosed with multiple myeloma and del(5q) MDS — Erik Rupard, MD (54:26) Journal Club with Dr Daver (57:28) CME information and select publications

Featuring perspectives from Dr Toby A Eyre and Dr Brad S Kahl, including the following topics: Introduction: Mantle Cell Lymphoma (MCL) and the General Medical Oncologist (0:00) Sequencing of Therapy for MCL: 2009-2025 (11:19) Cases and Questions from the Community (36:44) Case: A man in his early 80s with relapsed/refractory MCL with "brain fog" on zanubrutinib — Zanetta S Lamar, MD (56:07) CME information and select publications

Featuring an interview with Dr Joseph Mikhael, including the following topics: Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy for newly diagnosed multiple myeloma (MM) (0:00) KRd versus elotuzumab and KRd for transplant-eligible patients with newly diagnosed MM (10:47) Subgroup analysis of patients with 1q21 and other cytogenetic abnormalities in the Phase III IKEMA and ICARIA-MM studies (15:12) Results with ciltacabtagene autoleucel among patients with relapsed/refractory (R/R) MM in the CARTITUDE-1 study (26:59) CARTITUDE-4 study: Ciltacabtagene autoleucel in earlier lines of treatment for patients with lenalidomide-refractory MM (34:56) KarMMa-3 trial: Idecabtagene vicleucel for patients with R/R MM (44:20) GPRC5D-targeted CAR (chimeric antigen receptor) T-cell therapy for patients with R/R MM (49:09) Efficacy of teclistamab for R/R MM in the MajesTEC-1 trial (53:45) Efficacy of elranatamab for R/R MM in the MagnetisMM-3 trial (58:43) Efficacy of linvoseltamab for R/R MM in the LINKER-MM1 trial (1:02:01) Talquetamab for patients with R/R MM in the MonumenTAL-1 trial (1:04:16) Future directions in the first-line management of MM (1:06:03) Strategies to improve diversity and inclusion in clinical trials (1:10:53) CME information and select publications

Inside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung Cancer | Faculty Presentation 2: Novel Approaches to Adjuvant Treatment for Localized NSCLC CME information and select publications

Inside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung Cancer | Faculty Presentation 1: The Evolving Role of Neoadjuvant Therapy for Localized Non-Small Cell Lung Cancer (NSCLC) CME information and select publications

Featuring perspectives from Dr Jamie Chaft and Dr John V Heymach, including the following topics: Introduction: Patient Involvement in Adjuvant and Neoadjuvant Treatment Decisions (0:00) Targetable Treatment for Localized Disease (11:49) Immunotherapy for Localized Disease (35:57) CME information and select publications

Featuring an interview with Dr Michael Pishvaian, including the following topics: Importance of next-generation sequencing as part of the diagnostic workup for metastatic pancreatic cancer (0:00) Optimal treatment selection for patients with germline BRCA mutation-positive pancreatic cancer (3:32) NAPOLI-3 Phase III trial of liposomal irinotecan with 5-fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) versus gemcitabine/nab paclitaxel for treatment-naïve metastatic pancreatic ductal carcinoma (5:48) Perspectives on the comparative efficacy and tolerability of 2-drug and 3-drug treatment regimens in the metastatic setting; perioperative versus adjuvant therapy in locally advanced disease (9:22) Novel treatment approaches for pancreatic cancer — zolbetuximab, tumor treating fields and intra-arterial gemcitabine (14:35) Role of radiation therapy in the management of pancreatic cancer; early-phase data with novel antibody-drug conjugates (22:14) Selection of second-line therapy for metastatic pancreatic cancer (26:15) PARP inhibition for the treatment of pancreatic cancer (32:27) Investigational approaches for the treatment of KRAS mutation-positive pancreatic cancer (48:50) Vaccine-based treatment approaches under development for pancreatic cancer; palliative care strategies (52:04) CME information and select publications

Featuring an interview with Dr Matthew Matasar, including the following topics: Rationale for the evaluation of anti-CD20 x CD3 bispecific antibodies in the treatment of non-Hodgkin lymphoma (NHL) (0:00) Incidence, severity and time course of cytokine release syndrome, neurotoxicity/ICANS and other adverse events associated with bispecific antibodies; recommended mitigation and management protocols (4:39) Activity of and similarities and differences among the various bispecific antibodies for NHL (12:20) Eligibility, efficacy and durability of response with mosunetuzumab, glofitamab, epcoritamab and odronextamab; ongoing and planned evaluations of bispecific antibodies alone and in combination with other systemic therapies (19:18) Optimal integration of bispecific antibody platforms into treatment algorithms for patients with NHL (32:12) Emerging results with bispecific antibodies for mantle cell lymphoma and chronic lymphocytic leukemia (41:51) CME information and select publications

Featuring perspectives from Dr Kathleen N Moore, including the following topics: Introduction: SOLO-1 Trial (0:00) Case: A woman in her mid 50s with a germline BRCA1 mutation who received IV/IP chemotherapy followed by olaparib maintenance experiences disease recurrence — Neil Morganstein, MD (15:58) Case: A woman in her late 50s with a germline BRCA2 mutation undergoes surgery and chemotherapy for Stage II high-grade serous ovarian cancer (HGSOC) — Kellie E Schneider, MD (24:38) Case: A woman in her late 70s with a somatic BRCA2 mutation and Stage IVB HGSOC who experienced disease progression on the placebo arm of the PRIMA trial and recurrence in 2019 receives liposomal doxorubicin/carboplatin and maintenance niraparib — Karim ElSahwi, MD (30:37) Case: A woman in her early 50s presents with recurrent BRCA wild-type (WT), homologous recombination deficiency (HRD)-negative clear cell ovarian cancer after interval debulking surgery — Dana M Chase, MD (35:16) Case: A woman in her early 60s with BRCA WT, HRD-negative, folate receptor alpha-positive ovarian cancer experiences primary disease progression on neoadjuvant carboplatin/paclitaxel and receives mirvetuximab soravtansine — Priya Rudolph, MD, PhD (46:49) Investigator Survey (58:37) CME information and select publications

Featuring a slide presentation and related discussion from Dr Philippe Moreau, including the following topics: General overview of anti-CD38 antibodies in therapy for multiple myeloma (MM) (0:00) Anti-CD38 antibodies as part of first-line therapy for transplant-ineligible patients with MM (2:35) Quadruplet versus triplet induction regimens with anti-CD38 antibodies for newly diagnosed, transplant-eligible patients with MM (7:44) Clinical trial data with anti-CD38 antibodies for patients with MM at first relapse (13:02) Treatment options for patients with MM at second relapse and beyond (18:09) Subcutaneous formulations of daratumumab and isatuximab; CD38 as a target for other therapeutic strategies (21:00) CME information and select publications

Featuring an interview with Prof Philippe Moreau, including the following topics: Perspectives on efficacy outcomes with and toxicity profiles of daratumumab and isatuximab (0:00) Selection of an anti-CD38 antibody for initial treatment of multiple myeloma (MM) (7:28) Approach to maintenance therapy for transplant-eligible patients with MM (15:47) Management of MM in older patients; treatment approaches for t(11;14) MM (22:47) Management of relapsed/refractory MM (29:49) Management of anti-CD38 antibody-associated side effects (35:45) Other relevant clinical scenarios in MM — Plasma cell leukemia, smoldering myeloma (41:19) Perspectives on the future landscape of up-front treatment for MM (45:02) CME information and select publications

Featuring perspectives from Dr Kristen K Ciombor and Dr J Randolph Hecht, including the following topics: Introduction (0:00) Case: A woman in her early 80s with KRAS-mutated, HER2-positive metastatic colorectal adenocarcinoma — Zanetta S Lamar, MD (14:29) Case: A man in his late 70s with metastatic KRAS G12C-mutated rectal adenocarcinoma treated with third-line sotorasib/panitumumab — Georges Azzi, MD (26:03) Cases: A man in his late 50s with KRAS-mutated metastatic colon cancer and very slow disease progression on second-line FOLFIRI/bevacizumab, and a man in his mid 40s with KRAS wild-type metastatic colon cancer and disease progression on third-line treatment — Priya Rudolph, MD, PhD, and Ina J Patel, DO (30:41) Case: A man in his early 80s with right-sided microsatellite-stable (MSS), KRAS G12D-mutated metastatic colorectal cancer (mCRC), tumor mutational burden 10 mut/Mb, currently receiving third-line TAS-102 — Warren S Brenner, MD (37:11) Case: A man in his late 70s with microsatellite instability-high, BRAF V600E-mutated recurrent cecal adenocarcinoma — Nikesh Jasani, MD (50:09) Cases: A woman in her late 50s with MSS BRAF V600E-mutated mCRC with brain and bone metastases who experiences a good response to dose-reduced FOLFOX after disease progression on first-line encorafenib/cetuximab, and a woman in her mid 60s with RAS wild-type, BRAF V600E-mutated, MSS mCRC, now receiving encorafenib/cetuximab after disease progression on FOLFOX/bevacizumab — Farshid Dayyani, MD, PhD, and Dr Azzi (59:05) CME information and select publications

Practical Perspectives: Investigators Discuss Current Management and Actual Cases of Relapsed/Refractory Metastatic Colorectal Cancer | Faculty Presentation 2: Targeted Treatment for R/R mCRC — J Randolph Hecht, MD CME information and select publications

Practical Perspectives: Investigators Discuss Current Management and Actual Cases of Relapsed/Refractory Metastatic Colorectal Cancer | Faculty Presentation 1: Nontargeted Treatment Approaches for Relapsed/Refractory (R/R) Metastatic Colorectal Cancer (mCRC) — Kristen K Ciombor, MD, MSCI CME information and select publications

Featuring an interview with Prof Naveen Pemmaraju, including the following topics: Case: A woman in her mid 20s with classic blastic plasmacytoid dendritic cell neoplasm (BPDCN) who responded to combination hyper-CVAD/venetoclax (0:00) Defining and diagnosing BPDCN (5:17) Presentation, prevention and management of capillary leak syndrome (7:56) Targeting CD123 in BPDCN (12:53) Case: A man in his early 70s with TET-mutated BPDCN who had a complete response to tagraxofusp (14:21) Selection of CD123-targeted therapy for patients with BPDCN (20:05) Case: A man in his mid 60s who had a complete response to pivekimab sunirine (27:04) Future directions in the treatment of BPDCN (28:55) CME information and select publications

Featuring a slide presentation and related discussion from Prof Naveen Pemmaraju, including the following topics: Overview of blastic plasmacytoid dendritic cell neoplasms (0:00) Tagraxofusp: Development of the first FDA-approved targeted therapy for BPDCN (9:07) Integration of pivekimab sunirine into the management of BPDCN (20:31) Emerging novel therapies for patients with BPDCN and current role of chemotherapy-based regimens (26:02) Future directions in the management of BPDCN (33:26) CME information and select publications

Featuring perspectives from Dr Prithviraj Bose and Dr Andrew T Kuykendall, moderated by Dr Mascarenhas, including the following topics: Introduction (0:00) Clinical Decision-Making for Patients with Myelofibrosis (MF) — Dr Bose (2:27) Management of MF in Special Patient Populations — Dr Mascarenhas (19:26) Future Directions in the Management of MF — Dr Kuykendall (48:09) CME information and select publications

Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer | Faculty Presentation 2: Current and Future Role of Nonbiomarker-Based Strategies for Patients with Metastatic BRCA-Negative TNBC — Hope S Rugo, MD CME information and select publications

Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer | Faculty Presentation 1: Biomarker-Based Decision-Making for Patients with Metastatic BRCA-Negative, Triple-Negative Breast Cancer (TNBC) — Tiffany A Traina, MD, FASCO CME information and select publications

Featuring perspectives from Dr Hope S Rugo and Dr Tiffany Traina, including the following topics: Introduction: "Isn't Oncology Depressing?" (0:00) Checkpoint Inhibitors (13:37) Antibody-Drug Conjugates (30:04) HER2-Low Disease (54:25) Other Agents Under Development (59:54) CME information and select publications

Featuring an interview with Dr Paul G Richardson, including the following topics: Biologic rationale for targeting protein degradation pathways as a therapeutic approach in multiple myeloma (MM); mechanism of action of CELMoDs (0:00) Similarities and differences between iberdomide, mezigdomide and standard immunomodulatory drugs (7:14) Compassionate use of melflufen and belantamab mafodotin (12:08) Current management strategies for newly diagnosed MM (16:30) DETERMINATION: Evaluation of trial findings on racial and ethnic disparities and differential outcomes (23:02) Tailoring of up-front daratumumab-based therapies; management of extramedullary disease (33:17) CME information and select publications

Featuring a slide presentation and related discussion from Dr Paul G Richardson, including the following topics: Biologic rationale for targeting protein degradation pathways as a therapeutic approach in multiple myeloma (MM); mechanism of action of CELMoDs (0:00) Published efficacy and safety findings with iberdomide-containing combination regimens from the Phase I/II CC-220-MM-001 study (6:30) Emerging data with mezigdomide/dexamethasone for relapsed/refractory MM (13:22) Early results with and ongoing investigations of mezigdomide/dexamethasone in combination with a proteasome inhibitor (29:54) CME information and select publications

Featuring an interview with Dr Debra Richardson, including the following topics: Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors (0:00) Activity, safety and ongoing investigation of tumor treating fields in combination with chemotherapy for advanced ovarian cancer (5:12) ASCO and SGO guidance on the nationwide shortages of carboplatin and cisplatin (9:21) Investigating mechanisms of resistance to PARP inhibitors; potential use of circulating tumor DNA as an investigational tool (14:13) CME information and select publications

Featuring a slide presentation and related discussion from Dr Debra Richardson, including the following topics: Targeting folate receptor alpha in ovarian cancer; activity, tolerability and ongoing investigation of the antibody-drug conjugate (ADC) mirvetuximab soravtansine (0:00) Other ADCs under investigation for patients with ovarian cancer (20:05) Mechanism of action and activity of upifitamab rilsodotin (UpRi) for patients with pretreated ovarian cancer (23:27) Emerging strategies for patients with platinum-resistant ovarian cancer (29:53) Rationale for the discontinuation of clinical development of UpRi (33:17) CME information and select publications

Featuring perspectives from Dr Nicole Lamanna and Dr William G Wierda, including the following topics: Introduction: Mentoring Fellows (0:00) Case: A woman in her mid 50s with multiple cardiovascular comorbidities and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) receives bendamustine/rituximab induction followed by venetoclax/rituximab consolidation in a clinical trial — Spencer Henick Bachow, MD (11:47) Case: A man in his late 70s with relapsed del(11q) CLL develops atrial fibrillation while receiving ibrutinib — Warren S Brenner, MD (18:15) Case: A man in his early 70s with CLL develops rash and bruising while receiving ibrutinib — Gigi Chen, MD (27:02) Case: A man in his late 80s with CLL receives acalabrutinib as initial therapy and experiences thrombocytopenia — Kapisthalam (KS) Kumar, MD (31:42) Case: A woman in her mid 80s with relapsed CLL (TP53 mutation) discontinues ibrutinib due to bruising — Dr Brenner (40:08) Case: A man in his early 80s with R/R mantle cell lymphoma discontinues ibrutinib due to bleeding risks after a traumatic head injury — Dr Bachow (49:01) Case: A man in his late 50s with CLL and response to acalabrutinib develops worsening myalgias a year later — Eric H Lee, MD, PhD (58:36) CME information and select publications